Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab)
work together to treat patients with urothelial cancer. The study will compare these drugs to
other drugs that are usually used to treat this cancer (standard of care). The patients in
this study will have cancer that has spread from their urinary system to other parts of their
body.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.
Collaborators:
Merck Sharp & Dohme Corp. Seagen Inc. Seattle Genetics, Inc.